Introduction: From Gut Hormone to Global Research Phenomenon
The incretin revolution represents one of the most significant paradigm shifts in metabolic research history. What began as a curious observation in the 1960s — that oral glucose provoked a greater insulin response than intravenous glucose — has evolved into a multi-billion dollar research domain that has fundamentally changed our understanding of metabolism, appetite regulation, and cardiometabolic disease. The journey from the discovery of the incretin effect to the development of GLP-1 receptor agonists like semaglutide, dual agonists like tirzepatide, and triple agonists like retatrutide is a masterclass in translational science.
This article traces the complete arc of the incretin revolution — from its origins in basic gut hormone physiology through the engineering breakthroughs that created clinically viable GLP-1 agonists, to the current frontier of multi-receptor peptides that are redefining what’s possible in metabolic research.
Origins: The Incretin Effect
The Oral vs Intravenous Glucose Puzzle
In 1964, researchers McIntyre, Holdsworth, and Turner made a seminal observation: when healthy subjects were given oral glucose and intravenous glucose calibrated to produce identical blood glucose curves, the oral glucose consistently triggered 50-70% greater insulin secretion. This “incretin effect” — the amplification of insulin secretion by gut-derived factors beyond what glucose alone could explain — implied the existence of intestinal hormones that communicated nutrient ingestion to the pancreas before the nutrients themselves arrived.
The term “incretin” was coined to describe these putative intestinal insulin-stimulating hormones. The search for incretins would span decades and involve hundreds of research groups, ultimately identifying two principal incretin hormones: GIP (glucose-dependent insulinotropic polypeptide, discovered in the early 1970s) and GLP-1 (glucagon-like peptide-1, characterized in the mid-1980s).
Discovery of GLP-1
GLP-1 was identified through the cloning of the proglucagon gene in 1983 by Graeme Bell and colleagues. The proglucagon gene encodes multiple peptide hormones through tissue-specific post-translational processing: in pancreatic alpha cells, the primary product is glucagon, while in intestinal L-cells, the primary products are GLP-1 and GLP-2. The biologically active form, GLP-1(7-36)amide, was shown in 1987 to be a potent insulin secretagogue in humans, establishing it as a bona fide incretin hormone.
The Impaired Incretin Effect in Type 2 Diabetes
A critical observation that propelled GLP-1 into the therapeutic research spotlight was the discovery that the incretin effect is significantly impaired in type 2 diabetes. While healthy individuals derive approximately 50-70% of their postprandial insulin response from incretin hormones, this contribution drops to approximately 20-30% in type 2 diabetes. Importantly, this impairment is not due to reduced GLP-1 secretion (GLP-1 levels are largely normal in T2D) but rather to reduced responsiveness to GIP. GLP-1, however, retains most of its insulinotropic potency in T2D, making it an attractive therapeutic target.
The Engineering Challenge: Overcoming GLP-1’s 2-Minute Half-Life
The DPP-4 Problem
The major obstacle to using GLP-1 therapeutically was its extraordinarily short plasma half-life of approximately 1.5-2 minutes. This rapid degradation is primarily mediated by dipeptidyl peptidase-4 (DPP-4), a ubiquitous serine protease that cleaves the N-terminal two amino acids from GLP-1, converting the active GLP-1(7-36)amide to the inactive GLP-1(9-36)amide. Renal clearance further contributes to rapid elimination. Continuous intravenous infusion of GLP-1 demonstrated proof-of-concept (lowering glucose and suppressing appetite), but this delivery method was impractical for chronic use.
Two parallel strategies emerged to overcome this limitation: (1) inhibiting DPP-4 to prolong the action of endogenous GLP-1 (leading to DPP-4 inhibitors like sitagliptin) and (2) engineering DPP-4-resistant GLP-1 analogs with extended half-lives. The latter approach has proven far more impactful and represents the core of the incretin revolution.
Generation 1: Exenatide (Exendin-4)
The first generation of GLP-1 receptor agonists arose from an unexpected source: Gila monster venom. In 1992, John Eng discovered exendin-4 in the saliva of the Gila monster (Heloderma suspectum), a 39-amino-acid peptide with approximately 53% sequence homology to human GLP-1 but natural resistance to DPP-4 degradation. Exendin-4 (marketed as exenatide) became the first FDA-approved GLP-1 receptor agonist in 2005, with a half-life of approximately 2.4 hours — a 60-fold improvement over native GLP-1, but still requiring twice-daily injection.
Generation 2: Liraglutide — Albumin Binding
The second generation employed a more elegant engineering approach: attaching a fatty acid chain to the GLP-1 peptide that would bind serum albumin, creating a circulating depot. Liraglutide features a C-16 fatty acid (palmitic acid) attached via a glutamic acid spacer to lysine-26, plus an Arg?Lys substitution at position 34. This design extends the half-life to approximately 13 hours, enabling once-daily dosing. Liraglutide demonstrated, for the first time, that chronic GLP-1 receptor agonism could produce significant and sustained weight reduction in research settings.
Generation 3: Semaglutide — The Weekly Paradigm
Semaglutide represents the third generation, incorporating three synergistic modifications: Aib at position 8 for DPP-4 resistance, a C-18 fatty diacid with mini-PEG linker for enhanced albumin binding, and Arg?Lys at position 34 as the attachment point. These changes extend the half-life to approximately 7 days, enabling once-weekly dosing. Semaglutide’s success demonstrated that weekly GLP-1 agonism could produce weight reductions of 15-17% — results that transformed the field’s expectations for pharmacological metabolic intervention.
The Multi-Agonist Era
Dual Agonism: Tirzepatide
The incretin revolution’s most recent chapter involves moving beyond single-receptor targeting. Tirzepatide is a dual GIP/GLP-1 receptor agonist that simultaneously activates both incretin receptors. Based on the GIP sequence but engineered for GLP-1R cross-reactivity, tirzepatide has demonstrated weight reductions of 20-25% in research settings — exceeding semaglutide and approaching the efficacy of bariatric surgery.
The success of tirzepatide has validated the multi-agonist hypothesis and rehabilitated GIP as a metabolic target. The GIP component adds direct effects on adipose tissue (GIPR-mediated adiponectin release, adipose remodeling), broader CNS appetite regulation, and enhanced beta cell function through complementary intracellular signaling. The era of “the more receptors, the better” had begun.
Triple Agonism: Retatrutide
Retatrutide takes the multi-agonist concept to its current zenith: a single peptide molecule that activates three metabolic hormone receptors — GLP-1R, GIPR, and the glucagon receptor (GCGR). The addition of glucagon receptor agonism introduces hepatic glycogen mobilization modulation, enhanced thermogenesis and energy expenditure, direct lipolytic effects, and hepatic lipid oxidation. In phase 2 research, retatrutide produced weight reductions of up to 24% at 48 weeks, with the highest doses showing a trajectory suggesting even greater effects with longer treatment.
The Research Pipeline: What’s Next
The multi-agonist approach continues to evolve with several compounds in various stages of research:
- Survodutide: A dual GLP-1/glucagon agonist (without GIP) being studied primarily for MASH/NASH and metabolic liver disease
- Pemvidutide: Another GLP-1/glucagon dual agonist with a distinct binding profile
- Cagrilintide + semaglutide (CagriSema): A combination of an amylin analog with semaglutide, targeting the amylin pathway alongside GLP-1 for enhanced satiety
- Oral semaglutide optimization: Higher-dose oral formulations using SNAC absorption enhancer technology to deliver semaglutide without injection
- Small molecule GLP-1R agonists: Orally bioavailable non-peptide GLP-1 receptor agonists (orforglipron, danuglipron) that could dramatically improve accessibility
Beyond Metabolic Disease: The Expanding Research Frontier
Neurodegeneration
GLP-1 receptors in the brain mediate neuroprotective signaling through anti-inflammatory, anti-apoptotic, and neurotrophic mechanisms. Semaglutide is in Phase III trials for Alzheimer’s disease (EVOKE program), following preclinical evidence showing reduced amyloid-beta plaque formation, reduced tau phosphorylation, improved synaptic function, and reduced neuroinflammatory markers. The potential for GLP-1 agonists to treat neurodegenerative disease represents perhaps the most exciting frontier in the incretin revolution.
Cardiovascular Disease
The SUSTAIN-6, PIONEER-6, and SELECT trials demonstrated that semaglutide reduces major adverse cardiovascular events (MACE) in high-risk populations — including a 20% reduction in MACE even in non-diabetic populations with established cardiovascular disease (SELECT trial). These cardiovascular benefits appear to involve direct anti-inflammatory effects on vascular endothelium, reduction in epicardial adipose tissue, improved endothelial function and arterial compliance, and reduced atherogenic lipoprotein levels. Tirzepatide’s cardiovascular outcomes program (SURPASS-CVOT) and retatrutide’s cardiovascular research are ongoing.
Liver Disease (MASH/NASH)
Metabolic dysfunction-associated steatohepatitis (MASH, formerly NASH) has emerged as a major target for GLP-1 agonists and multi-agonists. Semaglutide demonstrated MASH resolution without worsening fibrosis in approximately 59% of treated subjects. Survodutide, with its glucagon receptor component targeting hepatic lipid metabolism directly, has shown even more dramatic hepatic fat reductions in early research.
Kidney Disease
The FLOW trial demonstrated that semaglutide reduces the risk of kidney disease progression in subjects with type 2 diabetes and chronic kidney disease by 24% — the first GLP-1 agonist to demonstrate renal protective effects in a dedicated kidney outcomes trial. The mechanisms likely involve improved glycemic control, reduced inflammation, improved renal hemodynamics, and potentially direct effects on tubular cell metabolism.
Addiction and Substance Use
Preclinical research and emerging observational data suggest that GLP-1 agonists may reduce alcohol consumption, nicotine seeking, and potentially other addictive behaviors. GLP-1 receptors in the ventral tegmental area (VTA) and nucleus accumbens modulate dopamine release and reward signaling, providing a mechanistic basis for anti-addiction effects. Clinical trials are underway to test semaglutide for alcohol use disorder.
The Science of Appetite: How GLP-1 Agonists Changed Our Understanding
Central Appetite Regulation
Perhaps the most profound impact of the incretin revolution has been on our understanding of appetite biology. GLP-1 agonists demonstrated that appetite is not simply a matter of “willpower” but rather a complex neurobiological process regulated by hormonal signals. The discovery that GLP-1 agonists could produce sustained appetite suppression — through direct activation of anorexigenic neurons, inhibition of orexigenic circuits, modulation of reward system activity, and alteration of food preferences — has fundamentally changed how researchers and clinicians think about energy balance regulation.
Challenges and Ongoing Research Questions
Muscle Mass Preservation
One significant concern with the substantial weight loss produced by GLP-1 agonists is the loss of lean mass alongside fat mass. Research indicates that approximately 25-40% of weight lost with GLP-1 agonists is lean mass, a ratio that raises concerns about sarcopenia, particularly in older adults. Active research is exploring combination approaches with resistance exercise, protein supplementation, and anabolic agents to preserve muscle during weight loss.
Weight Regain After Discontinuation
Studies consistently show that weight is regained upon discontinuation of GLP-1 agonists, with approximately two-thirds of lost weight returning within one year. This suggests that these compounds suppress rather than cure the underlying biological drives toward energy surplus, raising questions about optimal treatment duration and maintenance strategies.
Gastrointestinal Tolerability
Nausea, vomiting, and other gastrointestinal side effects remain the primary tolerability limitation of GLP-1 agonists, affecting 20-40% of subjects during dose titration. Research into mechanisms (direct GLP-1R activation on vagal afferents vs. central effects) and mitigation strategies (optimized titration schedules, anti-emetic co-treatments) continues.
Conclusion: A Revolution Still in Progress
The incretin revolution is far from complete. From its origins in basic gut hormone physiology, through the engineering breakthroughs that created viable GLP-1 receptor agonists, to the current frontier of multi-receptor peptides, this field has consistently exceeded expectations and expanded its scope. What began as a strategy for improving glucose control has become a comprehensive approach to cardiometabolic disease, neurodegeneration, liver disease, kidney protection, and potentially addiction.
For researchers, the progression from semaglutide (single GLP-1 agonist) to tirzepatide (dual GIP/GLP-1 agonist) to retatrutide (triple GLP-1/GIP/glucagon agonist) provides an unprecedented toolkit for investigating metabolic biology at multiple levels of complexity.